Neil Heider joined the MJ team in 2013 as risk management consultant in our Risk Management + Commercial Insurance department. Neil specializes in creating unique risk management programs for middle-market to upper-middle market companies. His expertise on the client side of the business has allowed him to view risk management from a different perspective.
Before MJ, Neil worked in both the construction and manufacturing industries where he oversaw production, quality, and safety standards. With over a decade of experience in these industries, Neil understands the business needs of our clients and the challenges they face on a daily basis. This insider knowledge helps him align clients’ risk management programs with their business goals and objectives to ensure progress.
Related Blogs
Employer Response to Pharma Shifts
Volatility in the pharmaceutical industry, including the expanding specialty drug pipeline, increased utilization of GLP-1 medications, and persistent supply chain disruptions, are contributing to rising costs ...
Read More
White House Launches TrumpRx, Unveils Drug Prices
On Feb. 5, President Donald Trump announced the launch of TrumpRx.gov, a federally operated website to help individuals buy prescription medications at discounted cash ...
Read More
DOL Issues Updated Model Employer CHIP Notice
The U.S. Department of Labor (DOL), through its Employee Benefits Security Administration (EBSA), has released a new model Employer CHIP Notice with information current ...
Read More
Prescription Drug Reporting (RxDC Report)
The No Surprises Act (NSA), enacted as part of the Consolidated Appropriations Act, 2021 (CAA), includes transparency provisions requiring group health plans to report ...
Read More
The MJ Foundation Awards $55,000 to Nashville Nonprofits Team Chad, Pathways Kitchen, and UpRise Nashville
NASHVILLE (Jan. 26, 2026) – The MJ Charitable Foundation (the MJ Foundation) has made major gifts to three Nashville nonprofits as part of its ...
Read More
Major Federal PBM Reforms Enacted as DOL Proposes New PBM Fee-Disclosure Rule
Federal oversight efforts directed at the pharmaceutical benefit manager (PBM) industry have expanded in recent years, culminating in several significant actions. On Feb. 3, ...
Read More